Valeant Pharmaceuticals Intl Inc: VRX May Not Be a Lost Cause After All - Nasdaq
Football Reporters OnlineValeant Pharmaceuticals Intl Inc: VRX May Not Be a Lost Cause After AllNasdaqThe bulk of its assets are stomach disorder treatments, such as Xifaxan, a drug for IBS.
Super Bowl 50: Xifaxan Ad - Wall Street Journal
Wall Street JournalSuper Bowl 50: Xifaxan AdWall Street JournalIrritable Bowel Syndrome can ruin the fan experience, as seen in this Super Bowl ad for Xifaxan.
Valeant's Latest Punch in the Gut: Patent Challenge on Xifaxan - Wall Street Journal (blog)
Wall Street Journal (blog)Valeant's Latest Punch in the Gut: Patent Challenge on XifaxanWall Street Journal (blog)The executives at Valeant Pharmaceuticals International are fighting a war on multiple sides.
Valeant missed huge on its 'billion dollar' savior drug — that should raise a big red flag - Business Insider
Business InsiderValeant missed huge on its 'billion dollar' savior drug — that should raise a big red flagBusiness InsiderRaffat said that although a lot of pharmacies canceled Xifaxan orders during Valeant's recent turmoil, prescriptions were still being filled.
FiercePharmaAllergan continues Viberzi push with online IBS-D awareness toolFiercePharmaOne of those options is, of course, Viberzi, the treatment that won FDA approval the very same day as Valeant rival Xifaxan.